Histamine H,-receptor antagonists have potential use in the management of gastrooesophageal reflux disease, because they inhibit basal, nocturnal, and stimulated. gastric acid secretion and pepsin secretion. [1] [2] [3] [4] Results of several trials with cimetidine show that treatment with this drug in the case of reflux oesophagitis usually results in a rapid symptomatic improvement, reduction in the amount of concomitant antacid consumption, and improvement of the reflux damaged mucosa as can be seen from endoscopic and histologic assessments.-"83 The new H2-recevtor antagonist ranitidine appears to be more potent and probably longer acting.9 Furthermore, some workers report a positive influence on the lower oesophageal sphincter pressure "' although this has not been confirmed." It therefore seemed appropriate to evaluate the efficacy of ranitidine in the acute treatment of reflux oesophagitis.
Methods

PATIENTS
Thirty eight adult outpatients were selected for this trial. The diagnosis was based upon a careful medical history, endoscopy, and biopsy. Informed consent was obtained from all patients.
MEDICAL HISTORY
All patients were asked to record the severity of heartburn, regurgitation, and retrosternal pain, previous treatment, and duration of the disease. The endoscopic findings at the end of the study were scored as unchanged (same degree), worse, or improved (when there was a change of at least one degree) or healed when compared to the pretrial findings. The degree of oesophagitis in the five or more pre-and post-trial endoscopic biopsies were defined as mild (grade I), moderate (grade II), and severe (grade III) using the criteria previously described.6 The pre-and post-trial biopsies were compared for each patient, and interpreted by experienced pathologists as unchanged (same degree), improved or worse (change of at least one degree). Only patients with endoscopically moderate or severe oesophagitis were admitted. Patients with concomitant ulcer, pregnant and lactating women, patients with previous oesophageal or stomach surgery, patients with strictures, and patients with serious diseases such as heart, liver, and kidney failure were excluded. The experimental results are summarised in Table 2 . Stage I There was a significant improvement in symptoms such as heartburn and regurgitation in the ranitidine treated patients. Less retrosternal pain was observed in this ranitidine group, although not significantly so. The daily antacid consumption was slightly lower in the second three week period in the ranitidine group. The difference was not significant. Using endoscopic criteria, 15 of the 19 ranitidine treated patients healed or were definitely improved, whereas four remained unchanged. In the placebo treated group, four patients healed or improved, 10 remained unchanged, and in three the oesophagitis 
became worse. The statistical difference between the incidence of healing or improvement vs lack of improvement between ranitidine and placebo treated patients was highly significant (p<O0O1). The overall histological gradings showed improvement or healing in 11 patients during ranitidine treatment, and in four patients during placebo treatment; also a significant difference (p<O.05).
Stage II The characteristics of the 18 patients who received a six week open treatment with ranitidine because they had not healed endoscopically in the stage I period, are summarised in Table 3 . As seen, eight patients were treated with ranitidine and 10 with placebo during stage I of the trial. The ex-placebo group had had more serious disease at the start of this stage II of the study regarding endoscopical and histological findings. Another six week treatment with ranitidine in the ex-ranitidine group resulted in improved symptomatology, endoscopical, and histological findings in approximately half of the patients, while this improvement was more pronounced in the ex-placebo group, now receiving ranitidine for six weeks, as can be also seen in Table 3 .
Discussion
The double blind prospective study (stage I) showed that ranitidine is superior to placebo in the acute treatment of patients with endoscopically moderate or severe reflux oesophagitis. 
